Pharmaceutical Kesios Therapeutics, a portfolio company of Imperial Innovations Group which is developing novel therapeutics for the treatment of multiple myeloma and other cancers, has closed a £19.0 million ($28.6 million) Series A funding round from a syndicate of leading venture investors including Innovations, SV Life Sciences and Abingworth. 2 December 2015